---
schema_version: "secwatch.filing_event.v1"
accession: "0001477449-23-000063"
form_type: "8-K"
ticker: "TDOC"
cik: "0001477449"
company_name: "Teladoc Health, Inc."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T13:54:59.235888+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teladoc Q3 revenue up 8% to $660.2M; adjusted EBITDA surges 73% to $88.8M

## Summary
- Net loss narrowed to $57.1M ($0.35/sh) from $73.5M ($0.45/sh) a year ago; adjusted EBITDA $88.8M.
- Integrated Care revenue +9% to $374.4M; BetterHelp revenue +8% to $285.8M.
- Operating cash flow $105.6M, free cash flow $68.0M; strong cash generation.
- Q4 guidance: rev $658-683M, adj EBITDA $107-117M; FY23 rev $2.60-2.625B, adj EBITDA $320-330M.
- CEO announces comprehensive operational review to drive efficiency and improve business performance.

## SEC filing metadata
- accession: 0001477449-23-000063
- form_type: 8-K
- ticker: TDOC
- cik: 0001477449
- company_name: Teladoc Health, Inc.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000063/0001477449-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000063/tdoc-20231024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477449-23-000063
- JSON: https://secwatch.observer/filing/0001477449-23-000063.json
- Plain text: https://secwatch.observer/filing/0001477449-23-000063.txt

## Key facts
- Earnings Releases
  Teladoc Health, Inc. reported the third quarter of 2023 results: revenue $660.2 million, net income $57.1 million, EPS $0.35 per share.
  - Period: the third quarter of 2023
  - Revenue: $660.2 million
  - Net income: $57.1 million
  - EPS: $0.35 per share
  - Result: reported results
  source text: Teladoc Health Reports Third Quarter 2023 Results • Third quarter 2023 revenue grows 8% year-over-year to $660.2 million • Third quarter 2023 operating cash flow of $105.6 million; free cash flow of $68.0 million • Third quarter 2023 net loss of $57.1 million, or $0.35 per share • Third quarter 2023 adjusted EBITDA of $88.8 million, up 73% year-over-year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744923000063/0001477449-23-000063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.